0001213900-24-002314.txt : 20240109 0001213900-24-002314.hdr.sgml : 20240109 20240109163011 ACCESSION NUMBER: 0001213900-24-002314 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20240109 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240109 DATE AS OF CHANGE: 20240109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Silo Pharma, Inc. CENTRAL INDEX KEY: 0001514183 STANDARD INDUSTRIAL CLASSIFICATION: APPAREL & OTHER FINISHED PRODS OF FABRICS & SIMILAR MATERIAL [2300] ORGANIZATION NAME: 04 Manufacturing IRS NUMBER: 462137136 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41512 FILM NUMBER: 24523625 BUSINESS ADDRESS: STREET 1: 677 N. WASHINGTON BLVD CITY: SARASOTA STATE: FL ZIP: 34236 BUSINESS PHONE: (718) 400-9031 MAIL ADDRESS: STREET 1: 677 N. WASHINGTON BLVD CITY: SARASOTA STATE: FL ZIP: 34236 FORMER COMPANY: FORMER CONFORMED NAME: Uppercut Brands, Inc. DATE OF NAME CHANGE: 20190808 FORMER COMPANY: FORMER CONFORMED NAME: Point Capital, Inc. DATE OF NAME CHANGE: 20130130 FORMER COMPANY: FORMER CONFORMED NAME: Gold Swap Inc DATE OF NAME CHANGE: 20110301 8-K 1 ea191279-8k_silopharma.htm CURRENT REPORT
false 0001514183 0001514183 2024-01-09 2024-01-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 9, 2024

 

Silo Pharma, Inc.

(Exact name of registrant as specified in its charter)

 

Nevada   001-41512   27-3046338
(State or other jurisdiction
of incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 

677 N. Washington Boulevard

Sarasota, FL

   34236
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (718) 400-9031

 

560 Sylvan Ave, Suite 3160

Englewood Cliffs, NJ 07632
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  

Securities registered pursuant to Rule 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of exchange on which registered
Common Stock, par value $0.0001 per share   SILO   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 8.01 – Other Events

 

On January 9, 2024, the Board of Directors of Silo Pharma, Inc. (the “Company”) approved an extension of the previously announced stock repurchase program authorizing the purchase of up to $1 million of the Company’s common stock until March 31, 2024.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

-1-

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  SILO PHARMA, INC.
     
Date: January 9, 2024 By: /s/ Eric Weisblum
    Eric Weisblum
    Chief Executive Officer

 

 

-2-

 
 EX-101.SCH 2 silo-20240109.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 silo-20240109_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 silo-20240109_pre.xml XBRL PRESENTATION FILE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Cover
Jan. 09, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 09, 2024
Entity File Number 001-41512
Entity Registrant Name Silo Pharma, Inc.
Entity Central Index Key 0001514183
Entity Tax Identification Number 27-3046338
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 677 N. Washington Boulevard
Entity Address, City or Town Sarasota
Entity Address, State or Province FL
Entity Address, Postal Zip Code 34236
City Area Code 718
Local Phone Number 400-9031
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol SILO
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 6 ea191279-8k_silopharma_htm.xml IDEA: XBRL DOCUMENT 0001514183 2024-01-09 2024-01-09 iso4217:USD shares iso4217:USD shares false 0001514183 8-K 2024-01-09 Silo Pharma, Inc. NV 001-41512 27-3046338 677 N. Washington Boulevard Sarasota FL 34236 718 400-9031 false false false false Common Stock, par value $0.0001 per share SILO NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://silopharmainc.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea191279-8k_silopharma.htm silo-20240109.xsd silo-20240109_lab.xml silo-20240109_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea191279-8k_silopharma.htm": { "nsprefix": "SILO", "nsuri": "http://silopharmainc.com/20240109", "dts": { "inline": { "local": [ "ea191279-8k_silopharma.htm" ] }, "schema": { "local": [ "silo-20240109.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "silo-20240109_lab.xml" ] }, "presentationLink": { "local": [ "silo-20240109_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://silopharmainc.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-01-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea191279-8k_silopharma.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-01-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea191279-8k_silopharma.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://silopharmainc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 13 0001213900-24-002314-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-24-002314-xbrl.zip M4$L#!!0 ( ,.#*5A\/O)@"1$ )E : 96$Q.3$R-SDM.&M?2MEJ@^+8H^^SNOH@TDYG)3&8R,TFZ\[_1P$)WA+N4V;LI M+:VF$+$-9E+[>C?E>SUE*_6_\NK*3M\#.("UW=U4W_.<4B8S' [3PVR:\>N, M5BP6,R,!DPJ 2J-$.%U5M(81DJ][K:-'<"\9_A$TXW%LNSW&!]@#'0I,>475%;T00Z*XQ)A !-_3U^SN M63Q;2E:+\,PH9W*DHKF+W0>)FV1*W!%-:( >>C8"Y*0W%VTA ZT1H.\JUQ@[ M#\ ]['8E8-@P@16><681-Q%:MDR &\RW/3Y.YCALG.C@ MH%QJ,:>/0<#4-M(&&PC0G*JIQ92T,()-^$3BSXY'/8N4=S+!)[0.B(>10*20 M6Y_>[::JS/:([2F=L0,B-X)ONRF/C+Q,8(@9T2\3HMWYEZ*@?4HLLX3:Q-M& M33P@)30R1]NH49._7*EZ]>J\_;=>.ZA43N%#C 0IRDM[9XM78KQ7,^.\BL;Y M"F2YPD.OMW3/%Z\(S#,8!/RK#(AMPG]OW\+75SULN>0UJ HQ5'4;-#*N BZ. MK89MDM$A&5^IX-;R6D[;>HVX"GL@[-J5=A6ZB( /'H-#OVJ#9(F[I5^)3UB M@,25SUZ#IR9X.0UQ96=8FHN\R\PQN68J M;/; &XCF@6.1P .$I":1!^12?9*X]%0;AY-"FN[\2"Z32"^DYH!,F3G+!:S_W*MACY0?AQ!A>FR; MZ08394ZGJ&6:K0D&HH>A&"=EZ]LT$"R8U(PT!P2[/B?ET/9* !,ABYHF20AL M<_ 'ACR71"@$"?1F&H\.8X8.&#>H<5:VHJ\T NPQ'FM^O0RF>4S"&B-:(S8; M4/LYLL_+99IN$N*H?4(*,P(-K3)F@X%+B/S>3@;ZPZ?XN^.\UL=NHP'FU]0N M(0&JIB"4<"2R^'+0\BVBG.)KN1K&/7+05_&8(_M'R)0N\SPV")\-J>GU!2_J MWZF)WEW&80A![ST+&S=(!QY<9E%S&X6-$::@77ML%P-47'H/2Q0\397_\Y=6 M4+<#880_8R/(3 QA0:**2#H_B/ 9^0GWH&"+7@-E UP;X2#&;OF\V>C4:ZC= MJ73J[9U,M[PL1MKUZGFKT6G4VZC2K*'ZU^JG2O.@CJHGQ\>-=KMQTEPF=Q?8 M[4..ZC' 6DM7TTA7\[GBTCA:[IS9/VD=HQW7P;;TS"*D*ZI5&;8J2HT9O@A] M1*)P93P$U8_A]7VSECVN7E*;7T-L]*80*$XC5=Y2#J=#GIV,X*[\F^H'#*E5 M;W90JWYZTNK\ID(X];GK8]M#'@-TAB@R("V+3EI(RZ^9ZXCU4*=/1)//J4>) MN[I2'QE];(-SKQB>:->*V=SO*#T1=HKQMXC#N(?6HN\$0TA!7 ^1.X!$7#83 M<[TD,K/RM$/0IQS"J8Q;ZT%4F^P9BK?J9[IOU+;XYJL\0U!&VDW1D58X)9E+ES]CV,1^CX@82>/^XD[@E32NV$BHV2$1;Y)JZHICG MB4P_6:^%[(W:,]UFX*0DSXV,*6'!]0:EYX;6CRC4$5*D6!!VH0% MP<1E'%RI+(2W/7!(U: 7&7F'(-RU"JN'GM'>9)[JZ,4-7I1F/"(P]F=F*&3 MGO(%O*7*37*'3?RDU86_>N:LED(=S%-!-!V3NO[D"JY.*'B?6@1DTR4\69N# MPMX7K7NRWV?9'W*/CW1$I4M3T_\H9UHYV0GE=/"H$=8 #3G+G])4WA[1 MD5U4[]N]']+4'**ILKZI9-5<(9O=>J'>X >/W.2L)I(=YGO+?$TZ"L0X8EZ? M&U9#&?-X:F9.XX%E\MV%466# 77%AC<2 M!HH"52]GO!^D_T:KC>H#QV)CPB.%3\YWU&3I]>1YG)$Q1WFY(?8O&_?,COV! MJUSQ[P>42TXQ]B=<=,4T.7'=\..(VD1+=L_9HV*^IU\>W1^9/^2>$PBFRH7- M3=1,H\=*(-ICO@4!$#>?33M^!ID6DF1:A5]/>(<-[62)O1.%!EAEB?MTA/':"??. M0P(=(:&DGSDF^$C2CY6N__RUI6N;VRZ 6<3I,YL@6T:0&R* MGP1C*RN8$XP M6(@)$@5S7)MGC\+_5@!TO@5N%IS:)^U+5O7>FHO&::3*F]J\3&9]QL$70RZ/ M&!C9J1CJ4[G8_?W^MX.][X??#V_>R.DTG50YIZH*)(C:SU9'7&X!.%]047ML MW8&R*G<$4/H4TKLLL+3,+=FZ?6V1(6,FJEJTUP.DS<](W2QD]2CE$-RM[3,. M.@Q+L%Q6P. K#EPHV% /!9L^X.G$8HXL[$9;&\LIQ"Y*U^$!@TDBWWT7DK!Q MJESM$X@8(#U'V'$X@W5$I.Q=-D)=8K&AD(MH%-)#6\KAZDJ/6N!I$'7![7C$ M-D%@'@.9#7S+PS9AOFN-D0O)G=L;RZYA!]8%RD'.QP*672).T(%(#HA-.*QW#1MP^,&^7B6MIP.^UTOO+;@/ M3Q2?S09ABB7$(%%PF7-&"PWVYA33+CCU8%J(8H=OATF^F^RX#R_40OZVT'?. MWUR\+G49LPBVYLO#)0>)L'BY!DR# ./E9- ^#[!5&A:00_TWJ>VHE6$CZDMJCY ME) 2@/ZQG2G;R86VTX:,S0!MVM?'X(3!$UO)AG/+L^?]O=N"WS 6;CBS//S, M5O/(+4S,@-U9D]%R6-'TF-5,G.]XL)F'P410 MPD]ZO7D)0_',[MW?;175KK5P\YG/R\]L1L"U8L38?G85TG*FHJ]UUU]F5 'L M'[/Z9YC59K)9-5S7)_Q9XSJT;R^R8Z_3/7Q=Z?T-QC7#T:]E8EFBY-:,EYE8 M"/ON)O9D+O0Q"6LLY T22,(A!9T5GW1/K+>Z(B0' OOU$L+?X<141UQ$##,]*DLCI,1L-^Q1FP:/9OV6S M1A[UZ,+8KCD#URJ,A_$2^JM:K=?W]S]\$V=>A3YT: MU[7;K3?6OJ?II,IBB059MSUFW&P@!W-TARV?H'^K:7%M$CGB?J6XJ_::57:) M>TKSTH;0N +;2A;OL>.;[J5^=WG:?:-X)XC XM4X.OF'B$US8UB8\4> [7Q+=SQ!S,:W2,^0WQT-%1 M=2DATU0JHJ:3$I%WBE,:MBFB3H*Z8V3(ZC_TN@'?2N0AO9K!%YSZ/5%].J(&!Z-I.)C^\2"05TPXTY\6X=*K?&@K<%"!U)8M984!]2 MH"WFC@U#@A9.[J@+_<"@L6V(8BHVY$MHY-D"\68C$W/3#?;DS*FTZ_%RW1I> MCSQ W%+3Z$'!"Y+QPI6VY OKL0OIB1?68Q?:?Z$+ZT_*7O"\#?"WOJB< -I@ M #(4FI7EU/W^>/(2UY6F)RBK((-%9U*WDK?X4*/W(\PPP F^4;H$# RX="37 M<9*%!(J"C=>2C"OUY];G' <(J5W#(P.TE89<0AYJTK;1B0P]ZN(ZJ;N8LR3+ M]_7),=Z)C:8NF6Y(1[G'P+/*ZQ URL&3,B[/]WPY53?M.V MUX,C''?@E\42(Q8!-W;/3B>@6T;O+HASKK(:)@3<.3@J%T!Q:XY'JRN M8-_K,T[OQ3HANT<0@,YWA,/_MX8@M;!B)&+\R*-J1I!*!D3$,F*)P!M2^*P6 MC/V=0[(/"K-GJPG#/A77B:.Y7A1S??]A497GAD416(36)JR1?=JEGIM>\,Q_ MBJV$*Y[O2U!+ MZJ*'62.NP:DC;ZV]^71XTIS@U]TU7&HK,\/T- MR]GQ6E[Y)IGR2P)G':(L.8?=DF @S-:VT1=1W/W N#J0ABUJ!=:+A))T4^T% MB5>JK$R^@S(0Q#82+PLJH0K'76I$KZ44PFHR(0)M(L*.>HD6Y9<._W^6>1Y_ M$UCCH%GIG+<6]3ZR)^DMSWCC+R@*:CRW/J0 ,CZ4"<%4)36I^+F15!TR?0CU M#>R+BHXLA :GV06=+D$N< 8-+'CE2)?TL=4352>!2!XY" $@,2,0NK/5%8DO M2@N(^5ZQ^Z]Q$SD+CE'$QA(Z_51I'5<@3VQ69V*Q'[K'%@JI M($*KIX*T:(/XA6";DW!O8G&!8A2O@"I-9^?)VW*+([HW+CT9G3T7]RYR'F7< M#*J+*O\%H6[7\@<_/(&2 \EWCBY_@2%4^Y3TP--'5SE/Y%5._K'![H.3L9CBZIJM>R7UO.;?OSQ4W[B#:]?NMZH \ZAX=Z*W-X,>I? MC@[VZ$&FF,F,AS0X= M;V3SKUHNX]:,(3O>H]B\5<\^?>N>_?>[<5RHY.WZ,8[0^;[=$9+N8'>XGO'#NED*M^L M^O#+)O'9URU3V[L@W^B J1W:^=IA0]]G=R:[&Y^=U[JX?W^357N%X]/*^>BP M7]G=#43R?U!+ P04 " ##@RE8Q_2KURX# #R"P $0 '-I;&\M,C R M-# Q,#DN>'-DM5;;]B?3!#<8$;\%KIEG]NB4G8-;&* 6^(XHXE R?@X> M(8FTA=U@@CCHLB D2"*UD7IJ@8;E.A"8YAZZCXCZC(_O>X7N7,I0M&Q[L5A8 ME+W!!>,OPO)8L)_@2$(9B4*M%M>R9S_Z NO(-LGHB%.XWO\-$/T+!H\/_F# M(73[P\F=C!O^V>O/ES@*OGZ>^!2>OGOL]L9]=KN/W\97S1]?'L:#U&5;>',4 M0*"*047'T/EEZ2WJ%N,SVZW5'/MIT!\E.",%MF*"Z6D/&$ MDURZ;NOM"12H4%:[N */J9"0>FMX7Q:$57##3C?7H'@K]"2%XASJHPV<0)XU M8V^VVE!XMYX#(V'.( P+\!2*22*:;:R!!9=EH#)N@DSY'B*Q%9INK1%&O?ZP MP I,6#B'/("8>KHQ-?1+S:DUU7@1%" J;Q@/KM$41D1%\QI!@J<8^0:0D,^0 MU)TF0NBA?23SGH64,M7::KXRB[:%(5:]6QB42=>ZQ1E!#RH)H!=JMBK\:(3= M9>J2, #V.T:Z7%',-7TTQ10G_K.!I!X$3F*NHROBIG9\],L'7,^5_=H"I)Y;.G.Z1@"ZQO1 MR&QSCJ;:1IB9%_672MM2G95#M(>*>4QJM'E2F>-< G*OI%*Z+Y0("Q&76+7W MRJ60AHZEIM^MN ':CS" _0\S)W!R:.:*@LA_3+FO]P&%!Y+PC@MAQ MM6_S+W;!]4*W4'U?ISL^$95.MW)L1*3(+4>'L/I!^8L8$IF#@E@KIR^YK26T MJ&NJ.M:=W>'\B9F\BZ.:P&,1E?S]D$98I>0OQU5C^2NP7R%R?%H$_7=PK-LC MNJ#L?%L+M.U432U_ U!+ P04 " ##@RE8_1P"^_T* " A@ %0 '-I M;&\M,C R-# Q,#E?;&%B+GAM;,V=76_CN!6&[POT/W#=FQ88QQ,'+9#L9!<9 M3[(P-IMD8\]LVT6QH"7&$4*3 24G]K\O*8FR1/%(2HJ2G(L9C_@>ZJ7XF*2^ MCC_]N-M0]$)$FG!V/CH^^CA"A$4\3MCZ?/1U,;Y8S.;S$4HSS&),.2/G(\9' M/_[PYS\A^>?3=^,QNDH(C<_0%QZ-Y^R!?X]N\(::8D([*@V/$9^OO1]!BC\7A O=\(B[GX>C^OZGW,LN?T;#)Y?7T] M8OP%OW+QE!Y%?#.LPD6&LVU:U?9Q]['\4X1_H@E[.E-_K7!*D#Q>+#W;IGD[R4BUM M*782SO-M[=X- A?K?6,O&:M/X>#H^ M.3[:I?%('_S\" I.R3UY0'DSS[+]LT0I310)HW+;HR /=C-4B(F*GS"RQAF) MU8Y.U8Z._Z%V])=R\S5>$3I"2BGY -MUVJBK#)JX-GM'1,+C2_8^UV:T)_OR MNR.R_Z$!]7CG35CR#--WF:]'.K=]0]YWQ ]Q[H^T'.?)^XYT+?+_8CMK6W[S MX;4?5ZHV7LM/#8MDE\D)C,3:I*JB8P3.]Y!/#&7=5>T\:M1+U6C.1;OM:F;, MZTQ)=+3F+Y.8)++NZ8GZ,%8?\F;+__PQXW(E<+%*,X&C3->4-^-\9"F?F):4 M\D)H7UA$/8TK%9.(RZGI.1O3XC 6X0^";ZR[+5O-+85_T%457QP6N0O :$,F M2,JW(B)OZI6Z6^@HE8XV5"K4DHJP\=?%Z(=<@W[7JO]\FAQJ<=#1<@FTW1"6 M+66-EA8TBUUUL\V4[N5Z61"=;#%D]K&6(*5QW,$7QVOD5Q6N+?:/<51=; M;>D^;A0&T=;C'9ZON:)BP$VL9@ M$FI:3P/[/5DG:FI1%M3Y+5$;.X8Q0.]ZZ.^T;<9.!-WW0M%2 MNN8"L&JB8 M0%8*.9:=VT+>0,43S/0) MI[O9;E9$6!K7EKAB S*GF3#+@V !,&4R4,B0TJ%"Z*7G]5T"EJF'&,'FF#*W M!-A--BEH:@(BP6H,H.&@S9\I]4+$3(Y, M,YB\GN9[('V]72N64"L-F$PA % M1(7=&8!%*4:Y&DFY%S#N1++!8K](HIZIHBUTBP9DM,F&J0H(#L :0$>I1HOY MS.=,LL2[>2Q!31Z2XGGP'DI O5M8>FPWF0'$ :'3[1 @2 :A9I1/D.8LXN*9 MUQYWF/&M' #W,Q[#*Y2>*+=0#6I"$ZW.D( &^(3P*P1^J%X)@5Q]1Y/7@%2 M-7@A[B*.Y8%*RW^N$T:.P?9;M6[IZK#;9,HB#(@DV!W 3ZG\H#\@%8-N62C0 M3-_0U*E_:*9#H9D&#: MF?QX*Y;\U?9P-JCT@DS;JA68@RP\7%K>^F!1 6H]HT)\8I(OK&[%G> O"8O@ M)3,D]P(,8-I*C:$-#QV[P3Y^J@6QCO,ZUA2+\MXOB9;Y&66:)NU#3*$)#Y*F ML=[!I5#[1.*.IQFF_TZ>.T_$[6(O>%@-6R%I*,-#Q6:O#Y@B!LD@'R?6):[J MAH;U53*CW-TKP!9;AU> :X5!0&!SU'X%N+AZ4HA<=[-B5! ,C C-8F>=;#%5 M]7&M+(PN;AMJ]7#^O98:'U]DE=V%WCUR!C\@T):XZFG(G.YMLSR('@=,F;V> MRU"N\W0U7F682.W#=ZW,VY[QS6;+ MRKL\MN<& 9VK7NZTJ7O<*@JB][N($ MF>R%J@CTR=:"1%LY/^Z/IZMEDE';R65;XFQ. LQ5,Y)1'@0;@"F3A;P,\0=T M//WKZF](1SGN_AN^%%@ECUWL-RM.@>Q35I4K"#HL:@XLDB!0@'V9--QP5$I1 MH?61G:IAUM( M%@%ZMT6*$#DNW:YHLL9 S5EK+(NE<38R4VC47VSC)2%R8 MN4H89E&":94>T79%O#_$&2T#S5?@].C#8&B8R19.19C.95@%'E)=NKZ47CR M\1NA]&?&7]F"X)0S$A?74FQWBKKU;I^8Z;'=?&@&$ >!TQ"'P*,S*FC\I**0 M#BNOA'DAZ1NG6Y9AD;]++FPC$Z!S2PY@LTF,(0J(%+LS@)!*C JUGQ>TB^P1 MU2*K^-TAL(&0W/'KVIVFC;>VK=J F.DT"+W#7>;\.*R-BRA/KUAF1/U>1/)" MON ,E][ ]D)RUR]5=IDVWZ:T:0-"J-,@^/YD%:-2Q6#-E+>4,6(FEUIKWO&4 MN*%RGSBF9;&=.Z:2!(2'S5='!AF!M-8+"XL-IO3S-DT82>&)R%"Y9<%JLBA9)(76^YX1E: MB;XHAY?OS021>J%B&)5SF(L; AUB9W_Z@AHN/7;(RUE M$"#UVH-_AZ2*0#K$,36WDF%1/X_+3WAY=X#9'CE;'%H+$PKBF"8 2T!2V+Z[\5X"=WWG9% MD^B*<@Q?96EH'&?,:]LSDN4=! $1T'8%ING_SY@]B>US%NWO!(\( M44]9I=5HU7?];6"T6V;>U*0F38-" ^+L+7X! @]5H%H='VHSEL^+>>JA<97- MC4=/BT^@$5 MP:@6[>G\+#UD 23QY_T]>2!"O7>P)+OLL]S14\<9QH!8UV=O@YMCGLSU!@8! MX5O=0J=Z*:I7@%;J&;&R"O2[J@3EM=A^O[R^Z5I^DIOU)OG7"J=$;ODO4$L# M!!0 ( ,.#*5BWYOOH6 < -]7 5 &ULS9Q=<]HX%(;O=V;_@Y>])@3H?B1-MI/0T&&:-MF0MKM[TQ&V $UDB9'D M /]^)1M3/BSYY,8GN4B(>?7Q/L>6?6S)%^]6*8^>J=),BLM6]^2T%5$1RX2) MV67KR[A]-1Z,1JU(&R(2PJ6@ERTA6^_^^OFGR/Y<_-)N1T-&>7(>O9=Q>R2F M\FWTF:3T//I !57$2/4V^DIXYK;((>-410.9+C@UU'Y1-'P>_7;2ZY*HW0;4 M^Y6*1*HO#Z-MO7-C%OJ\TUDNER="/I.E5$_Z))8IK,*Q(2;3V]I.5Z>;GZ+X M!6?BZ=S]FA!-(\M+Z/.59I=_-M2>J1<310OV^AWRNYL:[;?LH!^IR>:G>N\>[VTSD5?A_FN7LK;;U.[VVOWNR4HGK1)^3E!)3A_H-')_;?2VK6K&Y6).5$J8 MB%W4.D[1&4B[5]KNYF7GBDXO6TYIF^B].>V>GKD&?MT3F?6".I';N5I19Z_Q MA:*:"I/[O;4;]HK0E;'[%$W*BES[+^J>8<:5V.PVW:CM]K$LM0W:CX5RTYNR M/US&>UW@+A;RP&^Y7^?$-8U/9O*YDU!FR??Z[H.#T<]!V'^^YPU=3;11)#9E M39Q,*,_K_VXU!Y). [TJ23S:&JL[M:\X[--NY*Y4'$F54&59EW41%>_%ZW@7 MW2@Z"Z)L1>UXSO@VU%,E4Q^=#0GIZ>@N*-M$,S2O;/N)Z\.0DUDUS@,)D&<7 M VBE&RRB[ZF.%5LX+C5@]Y1 OCU4OA7>&L9<'CL/=,9!*B(SP![J0J@;\OA+(^PTF[RIO2)C_SH@R5/$UA/21& C[ M-TS8'H=(O!\5$9HY/A#@QVH@\=]1+SP\'I&0C^>4W?G=GEK@['>* /'_^5KP'[E%BL ]54PF]I2N .R/Q$#J9YC4/0Y1 M>=^(!$I[*P7G/_BP#^PAH1XR'1->]&AHM^DP[@HY%#E*SEEK$Q7[OY0H,/0= M,10Y2AI:8[%AX(-,J;W.!$<5OQJ*'"4!K3/9,/,;89A9N[O_G[-T\N/&Z3[K M8Q64,4K2Z3.%PK:\TR",>Z@1XGNHA#)&R35#YE X#ZP?1?A()'3UD:Y#H(^D M4-(H.6;0'@KJ>\52HM9C%MNK<( ME#U*6@FRBQ*"D8BE6LB=V\4#F=GC<3V027!(KRD(#0=*OOD"ZRA!N4H2BTMO M_MPR0;NA4%3*P<^(\ (0L/E*L/=>AKT'QXZ2A];:?"78^R_#WH=C1\E%:VUB M8A_8CW?J42X]3Z"]8BARE%RTQB(F\/Q,RH.NI'):#H$5/4L%G4 M';XXR4/V]E()Y8V8KE:;P^1\+[4A_#^VJ+N2K-9#F2,FKB&C3=]@+.+N;EKX MIA(=2*!\47+52CM-(W415I3X=]]]!10H2@):9:9AGK?2/?N82Q&\'WNL@G)% MR21]IIH>>-UL8NT]]'>^!L]@0QE6#VTTC/&;8L;V8"#3-!.;>S2>IV(>*10O M2OH7M-X6H&.'5G*MT4,@HR9[?6,.$[Q5UD:;VLCN?Q^66 M&ZB[Z=0W\H;T4.(HN5Z]45SR(ZTSJE[*OZ(4- HH:1_4=-/C#(TS.^RMN[W) MHULQXQEECE10UB@IG\]4PVP_RT=%W*J]\3J=2.Y?'E(IA!)&2? "UAJ&O->/ M:KP'$BA8E,RNT@[2F'"SBN=$S*A_]D*U$@H8)=,+F4,;>V>@L7?VPK$7)>/S MF4)B6\P-MT?4W82S&?&O) L6 *^SP20>L-KT^KU\R8];SZW2O!]#^Z$:NT<* M!8ZS1#)DKVG46<(,38HN#9D@(K8IU79=FR<[KR\%#0#.&DJ@:93;^]\HYQ^% M7(HQ)5H*FA27^J$[_-XBT"@@/D.LL8L2@J^29Y:2RB>"*L\QX)%"D2,^._38 MPYE[64QJWIY[BA=WA(C[2D#!(SY$#)M%FI]FJ.LS>Z;OB2&;'H;X^TI ^2,^ M4 R;19L_KP;VQ#.3X6?F!T(H;<2IL)764""/4\+Y=::9H#HXMAP(H9 1Y[Q6 M6D.!?)-2-;.#V@DUBOW8AC-Y&B.).+A"@/]9 >RAUU8:7?:,/D[\R"1@$E786:QCFW[JSD#YY:]W10WHB):94QG#53V82S>,@E"5Z7[\F@?!&S MT I;*'BOB7A2V<+$ZWLE8TK=XQ.]/=H "1&P FA($//3%Z' N5T@T]0M)I+Q MTWAN3>N[S.3O,;7]"]XT"):#A@9S$2? .-)5D/ZQT(LFU^L'.J7*35-XI"MS M;1MZ"E\4 8I#XX/Z1B$PAHHP772.?-W:#>Y-M<4W[I=[&ZO=\C]02P$"% ,4 M " ##@RE8?#[R8 D1 "90 &@ @ $ 96$Q.3$R M-SDM.&M?% &UL4$L! A0#% @ PX,I6+?F^^A8!P WU< !4 M ( !SA\ '-I;&\M,C R-# Q,#E?<')E+GAM;%!+!08 ..! $ T! !9)P ! end